Catalog No.
DHB87901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Stuart factor, Stuart-Prower factor, Coagulation factor X, F10, Plasma thromboplastin component, F9, Christmas factor, Coagulation factor IX, PTC
Concentration
1.16mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P00742, P00740
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, ACE-910, RG6013, hBS910, CAS: 1610943-06-0
Clone ID
Emicizumab
Emicizumab: Review of the literature and critical appraisal, PMID: 30431213
Emicizumab Prophylaxis in Hemophilia A with Inhibitors, PMID: 28691557
Emicizumab, PMID: 32644606
Emicizumab: A Review in Haemophilia A, PMID: 31542880
Emicizumab for hemophilia A without inhibitors, PMID: 31130012
Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A, PMID: 31203578
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors, PMID: 30157389
Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors, PMID: 31746522
Emicizumab treatment and monitoring in a paediatric cohort: real-world data, PMID: 32656767
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors, PMID: 31697801
Emicizumab for the prevention of bleeds in hemophilia A, PMID: 31150297
Emicizumab for the treatment of acquired hemophilia A, PMID: 32766881
Emicizumab-kxwh: First Global Approval, PMID: 29357074
Emicizumab for haemophilia A, PMID: 30765913
Emicizumab, PMID: 31643959
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study, PMID: 31003963
A hemophilia A mouse model for the in vivo assessment of emicizumab function, PMID: 32369559
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study, PMID: 33086400
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors, PMID: 31515851
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial, PMID: 31355677
Evaluating the safety of emicizumab in patients with hemophilia A, PMID: 30462521
Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures, PMID: 32311809
Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals), PMID: 32668090
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?, PMID: 29042366
Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors, PMID: 31887777
Emicizumab, PMID: 30000014
Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor, PMID: 33370499
Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays, PMID: 31064025
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors, PMID: 30430367
Laboratory issues in gene therapy and emicizumab, PMID: 32469128
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab, PMID: 31033112
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study, PMID: 30427582
Emicizumab for hemophilia A with factor VIII inhibitors, PMID: 30278802
Emicizumab in Hemophilia A, PMID: 32074440
Emicizumab in Hemophilia A, PMID: 32074441
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET, PMID: 31657709
Emicizumab in Hemophilia A. Reply, PMID: 32074442
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens, PMID: 28451690
Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma, PMID: 32892172
Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence, PMID: 32547043
Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A, PMID: 33236410
Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis, PMID: 32526092
Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A, PMID: 30612605
Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A, PMID: 32588417
Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions, PMID: 32906155
Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII, PMID: 32157756
[Emicizumab: a paradigm shift in hemophilia treatment], PMID: 32507821
Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis, PMID: 31373431
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab, PMID: 32237902
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A, PMID: 32717759
For research use only. Not for human or drug use.
